In September, Replit completed a $250M funding round that gave it a $3B valuation. That round was led by Prysm Capital and ...

With a new tool called Mobile Apps by Replit, users can describe their idea, let Replit do its thing, and then test the app on their iPhones.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Replit is racing to turn its AI coding tools into a full-stack software factory, and investors appear ready to bankroll that ...